Clinical Trials in Amersfoort, Netherlands
45 recruiting
Showing 1–20 of 61 trials
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled286 locationsNCT06925737
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled263 locationsNCT06717347
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled261 locationsNCT06841354
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled856 locationsNCT07181109
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
GlaxoSmithKline200 enrolled27 locationsNCT07227311
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1155 locationsNCT07064473
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting
Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Type 1 Diabetes Mellitus
Sanofi723 enrolled159 locationsNCT07088068
Recruiting
Phase 3
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
Rectal Cancer
Erasmus Medical Center103 enrolled25 locationsNCT07188025
Recruiting
Zimmer Biomet Shoulder Arthroplasty PMCF Study
Degenerative Joint DiseaseShoulder PainShoulder Fractures+3 more
Zimmer Biomet50 enrolled2 locationsNCT06920459
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled251 locationsNCT06793215
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled247 locationsNCT06750094
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled259 locationsNCT06312176
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled383 locationsNCT05920356
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb750 enrolled273 locationsNCT07361510
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled752 locationsNCT07157774
Recruiting
Prospective Data Collection Initiative on Colorectal Cancer
Colorectal, Cancer
Dutch Colorectal Cancer Group50,000 enrolled70 locationsNCT02070146
Recruiting
Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche2,000 enrolled486 locationsNCT05878769